Information

Related Research Units

Neurology Research

Education

Undergraduate School

Duke University
1997 Durham NC

Medical School

Harvard Medical School
2001 Boston MA

Internship

Pediatrics Boston Children's Hospital
2003 Boston MA

Residency

Pediatrics Boston Children's Hospital
2006 Boston MA

Fellowship

Multiple Sclerosis and Neuro-immunology Partners Adult and Pediatric MS Centers, Brigham and Women's Hospital and Massachusetts General Hospital
2008 Boston MA

Publications

  1. Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology. 2026 Oct 27; 107(8):e218508. View Abstract
  2. A 6-Year-Old With Becker Muscular Dystrophy and Catatonia. Pediatrics. 2026 Oct 01; 158(4). View Abstract
  3. Neurological manifestations and vasculopathy in PLCG2-associated antibody deficiency and immune dysregulation (APLAID): a case series. Pediatr Rheumatol Online J. 2026 Aug 29; 24(1). View Abstract
  4. Longitudinal stability of dietary intake patterns in pediatric-onset multiple sclerosis: A multicenter prospective cohort study. Mult Scler Relat Disord. 2026 Nov; 115:107677. View Abstract
  5. Cerebellar Atrophy in Pediatric-Onset Opsoclonus-Myoclonus-Ataxia Syndrome: A Large International Cohort Study. Neurol Neuroimmunol Neuroinflamm. 2026 Sep; 13(5):e200619. View Abstract
  6. Exploring Healthcare Continuity in Pediatric-Onset Multiple Sclerosis in the United States. Ann Child Neurol Soc. 2026 Sep; 4(3):177-187. View Abstract
  7. Telomere length as a marker of biological age in paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2026 Mar 13; 97(4):302-308. View Abstract
  8. Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis. Ann Neurol. 2026 03; 99(3):715-729. View Abstract
  9. Epigenetic age and telomere length correlations in pediatric-onset multiple sclerosis. Mult Scler. 2025 Dec; 31(14):1641-1650. View Abstract
  10. Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years. Neurology. 2025 Oct 21; 105(8):e214142. View Abstract
  11. Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry. J Child Neurol. 2026 04; 41(4):545-555. View Abstract
  12. Genetic Landscape of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. Pediatr Neurol. 2025 Dec; 173:33-40. View Abstract
  13. Epigenetic Aging in Pediatric-Onset Multiple Sclerosis. Neurology. 2025 Jun 24; 104(12):e213673. View Abstract
  14. Allele-specific vitamin D receptor binding is associated with pediatric-onset multiple sclerosis. Mult Scler J Exp Transl Clin. 2025 Apr-Jun; 11(2):20552173251335625. View Abstract
  15. Childhood adversity in parents of patients with pediatric multiple sclerosis. Mult Scler Relat Disord. 2025 Jun; 98:106424. View Abstract
  16. Limited early IVIG for the treatment of pediatric myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord. 2025 May; 97:106345. View Abstract
  17. Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025 Mar; 12(2):e200375. View Abstract
  18. Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis. Neurology. 2025 Feb 25; 104(4):e210213. View Abstract
  19. Distinct plasma lipids predict axonal injury and multiple sclerosis activity. J Neurol Neurosurg Psychiatry. 2025 Jan 16; 96(2):150-157. View Abstract
  20. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024 12 16; 96(1):68-75. View Abstract
  21. Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States. Neurology. 2024 Dec 10; 103(11):e209991. View Abstract
  22. Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis. Mult Scler. 2024 Oct; 30(11-12):1525-1543. View Abstract
  23. Early Adversity and Socioeconomic Factors in Pediatric Multiple Sclerosis: A Case-Control Study. Neurol Neuroimmunol Neuroinflamm. 2024 09; 11(5):e200282. View Abstract
  24. Isolated Psychiatric Symptoms in Children With Anti-N-Methyl-d Aspartate Receptor Encephalitis. Pediatr Neurol. 2024 Oct; 159:12-15. View Abstract
  25. Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis. Mult Scler. 2024 Jul; 30(8):1056-1065. View Abstract
  26. Inaugural Patient-Reported Registry of Pediatric Opsoclonus-Myoclonus-Ataxia Syndrome: Presentation, Diagnosis, and Treatment of 194 Patients. Pediatr Neurol. 2024 Sep; 158:128-134. View Abstract
  27. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul; 87:105647. View Abstract
  28. Multiomic Analysis of Neuroinflammation and Occult Infection in Sudden Infant Death Syndrome. JAMA Neurol. 2024 03 01; 81(3):240-247. View Abstract
  29. Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis. Mult Scler. 2024 Mar; 30(3):308-315. View Abstract
  30. Gene-environment interactions and risk of pediatric-onset multiple sclerosis associated with time spent outdoors. Mult Scler Relat Disord. 2024 Feb; 82:105351. View Abstract
  31. Assessing Needs and Perceptions of Research Participation in Pediatric-Onset Multiple Sclerosis: A Multistakeholder Survey. Pediatr Neurol. 2024 Feb; 151:115-120. View Abstract
  32. Short-chain fatty acid producers in the gut are associated with pediatric multiple sclerosis onset. Ann Clin Transl Neurol. 2024 01; 11(1):169-184. View Abstract
  33. Characteristics and predictors of disease course in children initially presenting with ADEM. Mult Scler Relat Disord. 2023 Oct 15; 80:105075. View Abstract
  34. Disease modifying treatment for pediatric onset multiple sclerosis: Ethical considerations and strategies to navigate parental refusal. Mult Scler Relat Disord. 2023 11; 79:104970. View Abstract
  35. MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2023 07; 10(4). View Abstract
  36. An International Pediatric-Onset Opsoclonus-Myoclonus Ataxia Syndrome Registry and Clinical Research Network: Development, Progress, and Vision. Pediatr Neurol. 2023 11; 148:145-147. View Abstract
  37. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Pediatr Neurol. 2023 08; 145:125-131. View Abstract
  38. Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2. Mult Scler. 2023 04; 29(4-5):576-584. View Abstract
  39. Silent findings: Examination of asymptomatic demyelination in a pediatric US cohort. Mult Scler Relat Disord. 2023 Mar; 71:104573. View Abstract
  40. Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder. Neurology. 2023 02 28; 100(9):e985-e994. View Abstract
  41. Mimics of Pediatric Small Vessel Primary Angiitis of the Central Nervous System. Ann Neurol. 2023 01; 93(1):109-119. View Abstract
  42. MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls. Ann Neurol. 2023 02; 93(2):271-284. View Abstract
  43. A new look at cognitive functioning in pediatric MS. Mult Scler. 2023 01; 29(1):140-149. View Abstract
  44. Evaluation of white matter microstructure in pediatric onset multiple sclerosis with diffusion compartment imaging. J Neuroimaging. 2022 11; 32(6):1098-1108. View Abstract
  45. An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome. J Rheumatol. 2022 Sep; 49(9):1042-1051. View Abstract
  46. Development of a multidisciplinary clinical approach for unexplained regression in Down syndrome. Am J Med Genet A. 2022 08; 188(8):2509-2511. View Abstract
  47. ZSCAN1 Autoantibodies Are Associated with Pediatric Paraneoplastic ROHHAD. Ann Neurol. 2022 08; 92(2):279-291. View Abstract
  48. Novel CAPN1 missense variants in complex hereditary spastic paraplegia with early-onset psychosis. Ann Clin Transl Neurol. 2022 04; 9(4):570-576. View Abstract
  49. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective. Neurol Neuroimmunol Neuroinflamm. 2022 05; 9(3). View Abstract
  50. A Single Stage Composite Cleft Septorhinoplasty for Correction of the Mature Unilateral Cleft Nose Deformity - The Gujrat Technique. Cleft Palate Craniofac J. 2023 Jul; 60(7):823-832. View Abstract
  51. Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. Mult Scler. 2022 08; 28(9):1330-1339. View Abstract
  52. Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology. 2022 01 18; 98(3):e267-e278. View Abstract
  53. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 11 01; 78(11):1333-1344. View Abstract
  54. Author Correction: Pan-viral serology implicates enteroviruses in acute flaccid myelitis. Nat Med. 2021 Oct; 27(10):1849. View Abstract
  55. Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome. Neurol Neuroimmunol Neuroinflamm. 2021 11; 8(6). View Abstract
  56. Gut microbiome is associated with multiple sclerosis activity in children. Ann Clin Transl Neurol. 2021 09; 8(9):1867-1883. View Abstract
  57. Functional analysis of a de novo variant in the neurodevelopment and generalized epilepsy disease gene NBEA. Mol Genet Metab. 2021 Sep-Oct; 134(1-2):195-202. View Abstract
  58. Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 09; 8(5). View Abstract
  59. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021 07; 8(5). View Abstract
  60. RCL1 copy number variants are associated with a range of neuropsychiatric phenotypes. Mol Psychiatry. 2021 05; 26(5):1706-1718. View Abstract
  61. Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop. Epilepsia Open. 2021 03; 6(1):62-72. View Abstract
  62. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). Child Neurol Open. 2020 Jan-Dec; 7:2329048X20979253. View Abstract
  63. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020 12; 7(12):2467-2474. View Abstract
  64. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain. 2020 09 01; 143(9):2733-2741. View Abstract
  65. IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study. Dev Med Child Neurol. 2020 12; 62(12):1444-1449. View Abstract
  66. Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology. 2020 09 29; 95(13):e1844-e1853. View Abstract
  67. Adherence to study drug in a stroke prevention trial"?>. J Stroke Cerebrovasc Dis. 2020 Oct; 29(10):105048. View Abstract
  68. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Mult Scler. 2021 10; 27(12):1814-1822. View Abstract
  69. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Ann Neurol. 2020 07; 88(1):42-55. View Abstract
  70. Posterior-onset Rasmussen's encephalitis with ipsilateral cerebellar atrophy and uveitis resistant to rituximab. Epilepsy Behav Rep. 2020; 14:100360. View Abstract
  71. Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations Responds to Immunomodulation. Pediatrics. 2020 02; 145(2). View Abstract
  72. Serial vessel wall MR imaging of pediatric tuberculous vasculitis. Neurol Clin Pract. 2019 Dec; 9(6):459-461. View Abstract
  73. Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Mult Scler. 2020 12; 26(14):1938-1947. View Abstract
  74. Pan-viral serology implicates enteroviruses in acute flaccid myelitis. Nat Med. 2019 11; 25(11):1748-1752. View Abstract
  75. SerpinB1 controls encephalitogenic T helper cells in neuroinflammation. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20635-20643. View Abstract
  76. Exploratory proteomic analysis implicates the alternative complement cascade in primary CNS vasculitis. Neurology. 2019 07 30; 93(5):e433-e444. View Abstract
  77. miRNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. Ann Clin Transl Neurol. 2019 Jun; 6(6):1053-1061. View Abstract
  78. Vitamin D genes influence MS relapses in children. Mult Scler. 2020 07; 26(8):894-901. View Abstract
  79. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol. 2019 05 01; 76(5):526-535. View Abstract
  80. Pediatric CNS-isolated hemophagocytic lymphohistiocytosis. Neurol Neuroimmunol Neuroinflamm. 2019 05; 6(3):e560. View Abstract
  81. Central nervous system-restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation. Blood Adv. 2019 02 26; 3(4):503-507. View Abstract
  82. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View Abstract
  83. Clinical Subpopulations in a Sample of North American Children Diagnosed With Acute Flaccid Myelitis, 2012-2016. JAMA Pediatr. 2019 02 01; 173(2):134-139. View Abstract
  84. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019 01; 15(1):e1007808. View Abstract
  85. Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. J Child Neurol. 2019 03; 34(3):148-152. View Abstract
  86. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke. 2019 Jan; 50(1):95-100. View Abstract
  87. Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children. Dev Med Child Neurol. 2019 09; 61(9):1108-1116. View Abstract
  88. Author Correction: Neuroimmune disorders of the central nervous system in children in the molecular era. Nat Rev Neurol. 2018 Dec; 14(12):749. View Abstract
  89. Histopathologic Correlates of Familial Hemophagocytic Lymphohistiocytosis Isolated to the Central Nervous System. J Neuropathol Exp Neurol. 2018 12 01; 77(12):1079-1084. View Abstract
  90. Health-related quality of life in children with inflammatory brain disease. Pediatr Rheumatol Online J. 2018 Nov 20; 16(1):73. View Abstract
  91. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology. 2019 04 30; 92(18):e2118-e2126. View Abstract
  92. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018 11 06; 91(19):e1778-e1787. View Abstract
  93. Several household chemical exposures are associated with pediatric-onset multiple sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1513-1521. View Abstract
  94. Urban air quality and associations with pediatric multiple sclerosis. Ann Clin Transl Neurol. 2018 Oct; 5(10):1146-1153. View Abstract
  95. Heterogeneity in association of remote herpesvirus infections and pediatric MS. Ann Clin Transl Neurol. 2018 Oct; 5(10):1222-1228. View Abstract
  96. Case 27-2018: A 3-Year-Old Boy with Seizures. N Engl J Med. 2018 Aug 30; 379(9):870-878. View Abstract
  97. Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing. JAMA Neurol. 2018 08 01; 75(8):947-955. View Abstract
  98. Neuroimmune disorders of the central nervous system in children in the molecular era. Nat Rev Neurol. 2018 07; 14(7):433-445. View Abstract
  99. Correction to: Impact of an electronic monitoring device and behavioural feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. Qual Life Res. 2018 04; 27(4):1117. View Abstract
  100. Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. Mult Scler Relat Disord. 2018 May; 22:103-107. View Abstract
  101. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018 Feb; 25(2):356-377. View Abstract
  102. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 02 01; 36(4):399-413. View Abstract
  103. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurol. 2017 11 01; 74(11):1319-1327. View Abstract
  104. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Circulation. 2018 01 30; 137(5):455-463. View Abstract
  105. Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018 01; 89(1):28-33. View Abstract
  106. Genetic risk factors for pediatric-onset multiple sclerosis. Mult Scler. 2018 12; 24(14):1825-1834. View Abstract
  107. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. J Neurol Neurosurg Psychiatry. 2018 01; 89(1):21-27. View Abstract
  108. Smoking cessation and outcome after ischemic stroke or TIA. Neurology. 2017 Oct 17; 89(16):1723-1729. View Abstract
  109. Examining the contributions of environmental quality to pediatric multiple sclerosis. Mult Scler Relat Disord. 2017 Nov; 18:164-169. View Abstract
  110. Dietary factors and pediatric multiple sclerosis: A case-control study. Mult Scler. 2018 07; 24(8):1067-1076. View Abstract
  111. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017 06; 30(3):334-344. View Abstract
  112. Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease. Neuropediatrics. 2017 Jun; 48(3):166-184. View Abstract
  113. Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. Qual Life Res. 2017 09; 26(9):2333-2349. View Abstract
  114. Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692. Diabetes Care. 2017 04; 40(4):e47-e48. View Abstract
  115. Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology. 2017 Apr 25; 88(17):1623-1629. View Abstract
  116. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. J Clin Endocrinol Metab. 2017 03 01; 102(3):914-922. View Abstract
  117. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017 Mar 14; 88(11):1012-1020. View Abstract
  118. Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis. Mult Scler. 2018 02; 24(2):175-185. View Abstract
  119. Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. Ann Clin Transl Neurol. 2016 12; 3(12):897-907. View Abstract
  120. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care. 2016 Oct; 39(10):1684-92. View Abstract
  121. Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics. 2016 07; 138(1). View Abstract
  122. Dietary salt intake and time to relapse in paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 12; 87(12):1350-1353. View Abstract
  123. A Diagnostic Score for Insulin Resistance in Nondiabetic Patients with Ischemic Stroke or Transient Ischemic Attack. J Stroke Cerebrovasc Dis. 2016 Jul; 25(7):1705-1712. View Abstract
  124. Voltage-gated potassium channel antibodies: Game over. Neurology. 2016 05 03; 86(18):1657-8. View Abstract
  125. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Apr 07; 374(14):1321-31. View Abstract
  126. A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Mult Scler Relat Disord. 2016 Mar; 6:87-92. View Abstract
  127. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e188. View Abstract
  128. Using Radiological Data to Estimate Ischemic Stroke Severity. J Stroke Cerebrovasc Dis. 2016 Apr; 25(4):792-8. View Abstract
  129. Autoimmune neurologic disorders in children. Handb Clin Neurol. 2016; 133:485-510. View Abstract
  130. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016 Jan 19; 86(3):245-52. View Abstract
  131. Pain and spinal cord imaging measures in children with demyelinating disease. Neuroimage Clin. 2015; 9:338-47. View Abstract
  132. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016 Apr; 22(4):470-82. View Abstract
  133. Reply: To PMID 24907434. Am J Ophthalmol. 2015 Jan; 159(1):211. View Abstract
  134. The Yield of Neuroimaging in Children Presenting to the Emergency Department With Acute Ataxia in the Post-Varicella Vaccine Era. J Child Neurol. 2015 Sep; 30(10):1333-9. View Abstract
  135. Evaluation and treatment of autoimmune neurologic disorders in the pediatric intensive care unit. Semin Pediatr Neurol. 2014 Dec; 21(4):284-90. View Abstract
  136. Impact of MS during the critical window of brain development. Neurology. 2014 Dec 02; 83(23):2106-7. View Abstract
  137. Protective environmental factors for neuromyelitis optica. Neurology. 2014 Nov 18; 83(21):1923-9. View Abstract
  138. The US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps. J Child Neurol. 2015 Sep; 30(10):1381-7. View Abstract
  139. Neuromyelitis optica in an adolescent after bone marrow transplantation. Pediatr Neurol. 2015 Jan; 52(1):119-24. View Abstract
  140. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J. 2014 Dec; 168(6):823-9.e6. View Abstract
  141. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 08; 83(2):142-50. View Abstract
  142. Visual outcomes in pediatric optic neuritis. Am J Ophthalmol. 2014 Sep; 158(3):503-7.e2. View Abstract
  143. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014 May; 71(5):569-74. View Abstract
  144. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurol. 2013 Nov 13; 13:173. View Abstract
  145. Clinical application and evaluation of the Bien diagnostic criteria for Rasmussen encephalitis. Epilepsia. 2013 Oct; 54(10):1753-60. View Abstract
  146. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014 Mar; 3(2):186-93. View Abstract
  147. Increased Th17 response to myelin peptides in pediatric MS. Clin Immunol. 2013 Mar; 146(3):176-84. View Abstract
  148. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler. 2013 Jun; 19(7):891-5. View Abstract
  149. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol. 2013 Jan; 28(1):102-7. View Abstract
  150. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol. 2012 Jan; 69(1):78-81. View Abstract
  151. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. 2011 Apr; 68(4):437-44. View Abstract
  152. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Curr Opin Pediatr. 2010 Dec; 22(6):745-50. View Abstract
  153. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 Jan; 66(1):54-9. View Abstract
  154. Postvaricella acute transverse myelitis in a previously vaccinated child. Pediatr Neurol. 2008 May; 38(5):370-2. View Abstract
  155. Neonatal hypocalcemic seizures in siblings exposed to topiramate in utero. Pediatr Neurol. 2007 Apr; 36(4):274-6. View Abstract

Contact Mark P. Gorman

Print Profile